Valiant Laboratories Quarterly Results for Trading Insights
In Mar 2026, Valiant Laboratories (VALIANTLAB) reported revenue ₹92 Cr and net profit ₹2 Cr — revenue +64.3% YoY. Compare with VALIANTLAB DCF valuation to assess whether the stock is under or overvalued.
VALIANTLAB Quarterly Results — Revenue, Profit & EPS Highlights
Valiant Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore VALIANTLAB price trends to track price trends across different timeframes.
- Revenue of ₹92 Cr in Mar 2026 (+95.7% vs Sept 2025, +64.3% vs Mar 2025)
- Net Profit of ₹2 Cr in Mar 2026 (+100.0% vs Mar 2025)
- EBITDA of ₹5 Cr in Mar 2026 (+400.0% vs Sept 2025)
- Operating Margin of 5.0% in Mar 2026
- Earnings Per Share of ₹0.32 in Mar 2026 (+700.0% vs Sept 2025)
Valiant Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VALIANTLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 92 | 47 | 56 | 48 | 53 | 95.7% | 64.3% |
| Net Profit (₹ Cr) | 2 | 0 | 1 | 2 | -7 | - | - |
| EBITDA (₹ Cr) | 5 | 1 | 2 | 3 | 0 | - | - |
| EPS (₹) | 0.32 | 0.04 | 0.16 | 0.42 | -1.30 | - | - |
| Operating Margin (%) | 5.0% | 0.0% | 7.0% | 5.0% | -2.0% | - | - |
VALIANTLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Valiant Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit VALIANTLAB screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VALIANTLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Valiant Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores